Yuichi Sato

Yuichi Sato

Auto-generated profile, based on publicly available information

Yuichi Sato

Department of Diabetes and Endocrinology, St Mary's Hospital , Kurume, Fukuoka 830-8543

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
MNMisao Nakanishi
Misao Nakanishi
NFNobuaki Funahashi
Nobuaki Funahashi
HFHideoki Fukuoka
Hideoki Fukuoka
TNTakao Nammo
Takao Nammo
YSYuichi Sato
Yuichi Sato
KYKazuki Yasuda
Kazuki Yasuda

3 March 2011 in Heart
Verified
Journal Article
Closed access
PDF file
SKShu Kasama
Shu Kasama
TTTakuji Toyama
Takuji Toyama
HSHiroyuki Sumino
Hiroyuki Sumino
HKHisao Kumakura
Hisao Kumakura
YTYoshiaki Takayama
Yoshiaki Takayama
MKMasahiko Kurabayashi
Masahiko Kurabayashi
Objective To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI). Design Single-centre, prospective, randomised evaluation study. Setting Patients with a first STEMI and single-vessel disease undergoing primary coronary angioplasty. Patients Sixty patients randomly assigned to two groups before angioplasty. Interventions Patients were randomly assigned to receive or not the spironolactone before primary coronary angioplasty. Main outcome The extent score (ES) was determined by use of 99mTc-pyrophosphate scintigraphy to evaluate the area of initial myocardial damage 3–5 days after primary angioplasty. The LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV) and LV ejection fraction were determined by echocardiography, and plasma procollagen type III aminoterminal peptide (PIIINP) was measured before and 3 weeks after treatments. The delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS) and washout rate (WR) were determined from 123I-meta-iodobenzylguanidine scintigraphy after 3 weeks. Results After primary angioplasty, age, gender, risk factors, culprit coronary artery, peak serum creatine kinase concentration, recanalisation time and ES were similar in the two groups. However, in the spironolactone group, the TDS and WR were significantly lower (TDS: mean (SD) 22.5 (8.0) vs 29.5 (10.1), p<0.005, WR: 30.5 (8.7)% vs 40.0 (10.9)%, p<0.001) and the H/M ratio was significantly higher (2.18 (0.37) vs 1.96 (0.30), p<0.05) than in the non-spironolactone group. Moreover, significant correlations were found between the degree of change in PIIINP concentration and change in LVEDV (r=0.559, p=0.001), or LVESV (r=0.546, p=0.002) in the spironolactone group. Conclusion Administration of spironolactone improves CSNA and prevents LV remodelling in patients with a first STEMI.

24 March 2005
Verified
Conference Paper
Closed access
HHH. Hermansky
H. Hermansky
Hiroshi FujisakiHiroshi Fujisaki
Hiroshi Fujisaki
YSY. Sato
Y. Sato
The Linear Predictive (LP) method has been widely used in speech analysis, mainly because of the simple mathematical formulation of the model and the straightforward computation of its parameters. However, there still remain certain difficulties that cause errors in the result of the analysis. Often encountered are the errors due to harmonic structure of the excitation source. The Spectral Transform LP (STLP) method proposed in the present paper aims at reducing these errors. Amplitude transforms on the input spectrum and on the spectrum of the model are introduced to modify the error criterion and the model adopted in the standard LP analysis. We show by analyses of both synthetic and natural speech that the STLP method offers significant improvement over the standard LP method. A method of STLP speech synthesis using the standard LP model is proposed. A perceptual experiment confirms the superiority of the STLP method in analysis of speech.

1 October 1993 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
KIKenzo Iino
Kenzo Iino
MYMototaka Yoshinari
Mototaka Yoshinari
KKKoichiro Kaku
Koichiro Kaku
MYMisao Yamamoto
Misao Yamamoto
YSYuichi Sato
Yuichi Sato
MFMasatoshi Fujishima
Masatoshi Fujishima

13 October 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
YSYuichi Sato
Yuichi Sato
KNKiyohide Nunoi
Kiyohide Nunoi
KKKohei Kaku
Kohei Kaku
AYAkihiro Yoshida
Akihiro Yoshida
HSHideki Suganami
Hideki Suganami
Aims: To investigate predictors of the initial response of beta‐hydroxybutyrate (BHB) and maximum BHB (max‐BHB) values during long‐term therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin (TOFO), and to explore the association of the initial elevation of BHB with subsequent clinical effects in people with type 2 diabetes mellitus. Methods: We analysed 774 people receiving TOFO in phase 3 trials in two groups based on measurable BHB change at week 4 (initial response): the top quartile [n = 194] and the three lower quartiles [n = 579]. Multivariate analysis was used to determine baseline predictors of inclusion in the top quartile and the max‐BHB values. To investigate the association of the initial response with subsequent clinical effects, adjusted changes in variables in the two groups were compared using an analysis of covariance model. Results: Of the participants, 66% were men, and the mean age, glycated haemoglobin, body mass index and estimated glomerular filtration rate were 58.5 years, 8.1%, 25.6 kg/m 2 and 83.9 mL/min/1.73 m 2 , respectively. Median changes in BHB at week 4 in the top quartile and lower three quartiles were +246.4* and +30.8* μmol/L, respectively (* P < .001 vs baseline). Lower baseline insulin secretion capacity predicted the inclusion in the top quartile and greater max‐BHB levels. The top quartile was associated with greater weight loss following greater increases in free fatty acids and greater reductions in fasting C‐peptide levels compared with the lower three quartiles. Conclusions: Lower basal insulin secretion capacity might predict greater initial BHB elevations and max‐BHB levels during long‐term TOFO therapy. Greater weight loss through lipid use might be related to high initial BHB elevations.

18 June 2021 in AACE Clinical Case Reports
Verified
Journal Article
Open access
MGMizuki Gobaru
Mizuki Gobaru
KSKentaro Sakai
Kentaro Sakai
YSYuki Sugiyama
Yuki Sugiyama
CKChiaki Kohara
Chiaki Kohara
AYAkiko Yoshimizu
Akiko Yoshimizu
HHHarumichi Higashi
Harumichi Higashi
The hyperosmolar hyperglycemic state (HHS), an acute complication of diabetes mellitus with plasma hyperosmolarity, promotes the secretion of anti-diuretic hormone (ADH) and reduces the storage of ADH. Magnetic resonance T1-weighted imaging reflects ADH storage in the posterior pituitary lobe, which disappears when the storage is depleted. Whether the HHS induces ADH depletion leading to clinical manifestations has been unclear. A 55-year-old Japanese woman was admitted to our center because of mental disturbance and hypotension. She had received lithium carbonate for bipolar disorder and presented with polydipsia and polyuria from 15 years of age. On admission, she had mental disturbance (Glasgow Coma Scale, E4V1M1), hypotension (systolic blood pressure, 50 mmHg), and tachycardia (pulse rate, 123/min). Plasma glucose was 697 mg/dL osmolality was 476 mOsm/kg•H2O, and bicarbonate was 23.7 mmol/L. The diagnoses of HHS and hypovolemic shock were made. During treatment with fluid replacement and insulin therapy, the urine volume continued to be approximately 3 to 4 L/day, and an endocrine examination revealed ADH insufficiency and nephrogenic diabetes insipidus. Desmopressin 10 μg/day and trichlormethiazide 2 mg/day were necessary and administered, and the endogenous ADH secretion improved gradually. The signal intensity of the pituitary posterior lobe, initially decreased on magnetic resonance T1 images, was also improved. This patient had ADH insufficiency associated with ADH depletion due to hyperosmolarity and nephrogenic diabetes insipidus. Clinicians should be aware of the risk of the development of critical HHS and relative ADH insufficiency in patients being treated with lithium carbonate.